Cell therapy manufacturing expert, Dr. Jonathan Esensten, joins Limula’s Strategic Advisory Board
Portrait of Dr. Jonathan Esensten.
- Limula appoints cell therapy expert, Dr. Jonathan Esensten, to its Strategic Advisory Board.
- The appointment supports the development of LimONE, Limula’s integrated platform for automated cell and gene therapy (CGT) manufacturing.
Lausanne, Switzerland, April 1, 2025 – Limula, an emerging life science tools company specializing in automated Cell and Gene Therapy manufacturing solutions, has appointed Dr. Jonathan Esensten to its Strategic Advisory Board. This announcement follows the unveiling of the design of LimONE, Limula’s flagship product. The company’s proprietary technology combines a bioreactor and centrifuge to support all cell therapy manufacturing steps into a single platform.
Dr Esensten is a physician-scientist who serves as the director of the Advanced Biotherapy Center at Sheba Medical Center, Israel. He has extensive experience in the development and adoption of new technologies for manufacturing of cellular therapy products. During his time at University of California (UCSF) and Sheba, Dr Esensten has successfully led multiple cell therapy projects with academic partners, large biopharma, and small biotechnology firms. He trained in cellular immunology, clinical pathology, and transfusion medicine at UCSF. He was on the faculty of the Department of Laboratory Medicine at UCSF from 2017-2023.
Dr Esensten commented: “I am delighted to join the Limula Strategic Advisory Board at this exciting stage of the company’s development. I look forward to working with their Head of Solutions, Dr. Caroline Boudousquié, and the entire team to maximize the impact of their promising technology.”
Limula CEO Dr. Luc Henry added: “Jonathan brings deep scientific expertise that will be instrumental in refining experimental strategies. His guidance will help strengthen our approach in translating technology differentiation into better cell products for our customer, and to support the further development of our products. By providing an external perspective and leveraging his network, Jonathan will also ensure our scientific activities align with industry best practices and future innovations and enhance collaboration opportunities.”
Over the first months of the year, Limula has also strengthened its team by adding key profiles with extensive experience in cell therapy and life science tools, particularly in Product, Industrialization and Manufacturing.
About Limula
Limula SA is a life science platform technology company based in Lausanne, Switzerland, dedicated to transforming the manufacturing of Cell & Gene Therapies. Their mission is to accelerate the development and commercialisation of new advanced therapies through an automated, on-demand, and scalable manufacturing solution. Limula’s proprietary platform integrates all functionalities into a single device, empowering therapeutics developers to bring life-saving treatments to patients more efficiently.
Contact Details
Luc Henry, DPhil
[email protected]
www.limula.ch